RibociclibMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3601428/fr/kisqali-ribociclib-cancer-du-sein
2025
false
false
false
France
treatment outcome
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
evaluation of the transparency committee
neoplasm, malignant
Kisqali
breast cancer
ribociclib
breast neoplasms
ribociclib

---
https://ansm.sante.fr/informations-de-securite/kisqali-ribociclib-changement-des-conditions-de-conservation-et-de-la-duree-de-conservation
2025
false
false
false
France
French
drug information
guideline
drug storage
ribociclib

---
https://ansm.sante.fr/actualites/essai-clinique-ribolaris-dans-le-cancer-du-sein-precoce-suspension-partielle-et-modification-des-modalites-de-realisation-de-lessai-clinique
2024
false
false
false
France
French
drugs, investigational
Clinical Trial Suspension
breast neoplasms
drug impurity
nitrosamines
ribociclib
pharmacovigilance note

---
https://www.has-sante.fr/jcms/p_3404153/fr/kisqali-ribociclib-cancer-du-sein
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
antineoplastic agents
protein kinase inhibitors
ribociclib
antineoplastic combined chemotherapy protocols
Letrozole
Letrozole/Ribociclib Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
neoplasm metastasis
evaluation of the transparency committee
breast cancer
ribociclib
breast neoplasms

---
https://www.cancer.fr/catalogue-des-publications/inhibiteurs-des-cdk-4-et-6-abemaciclib-palbociclib-ribociclib
2022
false
false
false
France
practice guideline
ribociclib
abemaciclib
ribociclib
palbociclib
palbociclib
abemaciclib

---
https://www.has-sante.fr/jcms/p_3229924/fr/kisqali
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
ribociclib
ribociclib
Ribociclib Succinate
antineoplastic combined chemotherapy protocols
Fulvestrant/Ribociclib Regimen
Fulvestrant
antineoplastic agents
breast neoplasms
postmenopause
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
protein kinase inhibitors
evaluation of the transparency committee
aminopyridines
purines

---
https://www.has-sante.fr/jcms/p_3097597/fr/kisqali
2020
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
ribociclib
ribociclib
Fulvestrant/Ribociclib Regimen
Fulvestrant
postmenopause
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
breast neoplasms
survival analysis
insurance, health, reimbursement
antineoplastic agents
evaluation of the transparency committee
aminopyridines
purines

---
https://www.has-sante.fr/jcms/p_3199713/fr/kisqali
2020
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
administration, oral
ribociclib
ribociclib
antineoplastic combined chemotherapy protocols
breast neoplasms
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
antineoplastic agents
protein kinase inhibitors
treatment outcome
aminopyridines
purines

---
https://www.has-sante.fr/jcms/p_3103868/fr/kisqali
2019
false
false
false
France
breast neoplasms
antineoplastic combined chemotherapy protocols
ribociclib
ribociclib
antineoplastic agents
aromatase inhibitors
Letrozole
Anastrozole
adult
evaluation of the transparency committee
aminopyridines
purines

---
https://www.has-sante.fr/jcms/c_2827573/fr/kisqali
2018
false
false
false
France
French
treatment outcome
ribociclib
ribociclib
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Locally advanced breast cancer
breast neoplasms
postmenopause
Stage IV Breast Cancer AJCC v6 and v7
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
HER2/Neu Negative
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
antineoplastic combined chemotherapy protocols
adult
aged
ribociclib
evaluation of the transparency committee
guidelines for drug use
aminopyridines
purines
aminopyridines
purines

---
https://www.ema.europa.eu/medicines/human/EPAR/Kisqali
2017
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ribociclib
ribociclib
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Locally advanced breast cancer
breast neoplasms
postmenopause
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
drug monitoring
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
adult
aged
drug interactions
drug evaluation, preclinical
ribociclib
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
Fulvestrant/Ribociclib Regimen
aminopyridines
purines
aminopyridines
purines

---